Please login to the form below

Not currently logged in
Email:
Password:

Ferring appoints executive VP and chief medical officer

Professor Klaus Dugi joins the pharma group from Boehringer Ingelheim

Klaus DugiFerring Pharmaceuticals has appointed professor Klaus Dugi as its executive vice president and chief medical officer; roles that will see him take the helm of its global medical affairs, quality assurance and pharmacovigilance business.

Prior to his new role, Professor Dugi has held various leadership roles at Boehringer Ingelheim, including vice president, global affairs, chief medical officer, and most recently managing director UK and Ireland.

Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals, said: “Making the industry more patient-centric has always been a top priory for Professor Dugi, and this is perfectly aligned with our company philosophy and commitment so solving unmet patient needs, particularly in the area of reproductive and maternal health.”

Additionally, Professor Dugi will also be a member of the Swiss group’s medical board, effective immediately.

12th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics